Francisco Partners Sells $5.5M GoodRx Stake, Nearly Exits Position
GDRX sits 97% above its 52-week low of $1.77.
Summary
Francisco Partners sold $5.5 million of GoodRx stock over three days, nearly exiting its position after a series of recent sales.
Key Events · Ownership and Investor Activity · GDRX
-
Francisco Partners Sells $5.5M Stake
Sold 1,567,044 shares at $3.44-$3.51 per share between August 24-26, 2026, for total proceeds of $5,477,482.
-
Near-Complete Exit
Post-transaction holdings fell to 716,801 shares, with Francisco Partners IV, L.P. and IV-A, L.P. each reaching zero shares in their respective accounts.
-
Follows Prior Disclosures
This sale follows a Form 144 filed August 19 for 2.76 million shares and a $4.2 million sale on August 22, confirming a deliberate exit strategy.
-
Contrasts with Strong Q2 Results
The sales come despite GoodRx's Q2 revenue beat of $200.4M vs $193.2M consensus on August 5, suggesting the firm is monetizing its position rather than reacting to fundamentals.
Analysis · GDRX · Technology
A 10% owner, Francisco Partners, sold 1.57 million GoodRx shares for $5.5 million between August 24-26, reducing its stake to just 716,801 shares. This follows a Form 144 filed August 19 and a $4.2 million sale on August 22, confirming a deliberate exit by the private equity firm. The sales come despite GoodRx's strong Q2 earnings beat on August 5, suggesting the firm is monetizing its long-held position rather than reacting to company fundamentals.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GDRX was trading at $3.48 on NASDAQ in the Technology sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $1.77 to $5.81. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.